GARRETT SCOTT T 4

What Happened

Garrett Scott T, a director of HCW Biologics Inc. (HCWB), reported two related purchase entries on a Form 4 dated 2026-05-27 for transactions on 2026-05-22. The filing shows a purchase of 177,936 shares at $1.41 per share (total $250,000). A second entry records an acquisition of 177,936 derivative shares at $0.00; a footnote states these shares were purchased directly from the issuer in a private placement and are exempt under Rule 16b-3(d).

This was a purchase (insider buying stock), which market participants often view as a stronger signal than routine sales — but filings are factual only and do not state the insider’s motivation.

Key Details

• Transaction date: 2026-05-22; Form 4 filed: 2026-05-27 (filed within the required two business-day window).
• Primary purchase: 177,936 shares at $1.41 each — total reported cash paid $250,000.
• Additional entry: 177,936 derivative-class acquisition reported at $0.00 (same share count as the cash purchase).
• Footnote: The reporting person purchased these shares directly from the issuer in a private placement, exempt from Section 16(b) per Rule 16b-3(d).
• Shares owned after the transaction: Not specified in the supplied filing details.

Context

• The reporting code "P" denotes purchase. The combined entries and the footnote indicate this was a private placement transaction with a related derivative entry recorded for reporting purposes.
• Purchases by directors can be interpreted as a show of support, but they do not guarantee future company performance. This Form 4 is informational only and does not disclose intent or future plans.